UBS lowered the firm’s price target on AtriCure (ATRC) to $58 from $60 and keeps a Buy rating on the shares. Strength in AtriCure’s core business was enough to offset minimally invasive surgery weakness and sustain long-term low double digit growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure price target lowered to $52 from $58 at BTIG
- AtriCure price target lowered to $51 from $52 at Canaccord
- Atricure’s Strong Q1 2025 Performance and Conservative Guidance Justifies Buy Rating Despite Price Target Adjustment
- AtriCure, Inc. Reports Strong Q1 2025 Growth
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M